9 Meters Biopharma Inc (NMTRQ)

9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company listed on OTC Markets under the ticker NMTR.Q. The company has focused on developing therapies for rare digestive diseases, gastrointestinal conditions with unmet medical needs, and other debilitating disorders in North America. Its pipeline has included Vurolenatide, a long-acting injectable GLP-1 candidate in Phase 3 testing for short bowel syndrome, along with NM-136 for obesity and obesity-related disorders, NM-102 for preventing antigen trafficking into systemic circulation, and NM-003 for the prevention of acute graft-versus-host disease. The company has also partnered on Larazotide, which has been in Phase 2 development for multisystem inflammatory syndrome. 9 Meters Biopharma is headquartered in Raleigh, North Carolina, and has disclosed licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. On July 17, 2023, the company filed a voluntary Chapter 7 liquidation petition in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.